类风湿关节炎患者痴呆发病率及与改善病情抗风湿药的相关性——基于全国理赔数据库的分析
基于2006—2017年美国联邦医疗保险与医疗补助服务中心(CMS)理赔数据,纳入141,326例≥40岁类风湿关节炎(RA)患者,比较使用生物制剂或靶向合成改善病情抗风湿药(b/tsDMARD)与仅用传统合成改善病情抗风湿药(csDMARD)者的新发痴呆风险。b/tsDMARD组较csDMARD组痴呆风险 adjusted 降低19%(HR 0.81,95%CI 0.76-0.87),TNFi、非TNFi与tsDMARD亚组间风险降低程度相当。
要点
- b/tsDMARD组较csDMARD组痴呆风险 adjusted 降低19%(HR 0.81,95%CI 0.76-0.87)。
- 粗发病率:csDMARD组2.0/100人年(95%CI 1.9-2.1),b/tsDMARD组1.3/100人年(95%CI 1.2-1.4)。
- TNFi、非TNFi与tsDMARD亚组间痴呆风险降低程度相当。
核心结论
- 在RA患者中,接受b/tsDMARD者新发痴呆风险低于仅用csDMARD者(HR 0.81,95%CI 0.76-0.87)。
- 不同类别b/tsDMARD之间未见差异,作者认为风险降低可能由炎症总体下降而非某类药物特定机制解释。
研究设计与样本
- 分析2006—2017年CMS理赔数据,以≥40岁、风湿科医生两次RA诊断间隔>7天且<365天识别RA患者,排除既往痴呆诊断者。
- 暴露分为b/tsDMARD暴露(含TNFi-bDMARD、非TNFi-bDMARD或tsDMARD,可联用或不联用csDMARD)与csDMARD暴露(任何csDMARD但未用b/tsDMARD);患者换药可贡献不同暴露组人时。
- 新发痴呆定义为1次住院或2次门诊ICD-9-CM或ICD-10痴呆理赔,或处方痴呆特异性药物(利斯的明、加兰他敏、美金刚、多奈哌齐、他克林)。
- 计算年龄调整发病率,并用单因素与多因素Cox比例风险模型计算HR及95%CI。
- 共识别141,326例符合条件RA患者;80%为女性、75.3%为白人,中位年龄67岁,平均(SD)暴露时间1.1(1.5)年。
主要发现
- 随访期间b/tsDMARD或csDMARD启用共233,271次,新发痴呆3,794例。
- csDMARD组痴呆粗发病率为2.0/100人年(95%CI 1.9-2.1),任何b/tsDMARD组为1.3/100人年(95%CI 1.2-1.4)。
- b/tsDMARD组较csDMARD组痴呆风险 adjusted 降低19%(HR 0.81,95%CI 0.76-0.87)。
- 亚组分析显示TNFi、非TNFi与tsDMARD之间痴呆风险降低程度相当。
关键数值与推荐
- 新发痴呆判定:1次住院或2次门诊ICD-9-CM或ICD-10痴呆理赔,或处方利斯的明、加兰他敏、美金刚、多奈哌齐、他克林之一。
- RA识别标准:成人≥40岁且风湿科医生两次RA诊断间隔>7天且<365天。
- 主要效应量:b/tsDMARD组较csDMARD组 HR 0.81(95%CI 0.76-0.87)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the risk of incident dementia associated with the use of biologics or targeted synthetic DMARDs (b/tsDMARD) compared to conventional synthetic (cs) DMARDS only in patients with rheumatoid arthritis (RA). METHODS: We analyzed claims data from the Center for Medicare & Medicare Services (CMS) from 2006-2017. Patients with RA were identified as adults ≥40 years old and two RA diagnoses by a rheumatologist > 7 and < 365 days apart. Patients with a prior diagnosis of dementia were excluded. Use of cs/b/tsDMARDs was the exposure of interest. Person-time was classified as either: 1) b/tsDMARD exposed, which included tumor necrosis factor alpha inhibitors (TNFi)-bDMARDs, non-TNFi-bDMARDs or tsDMARDs with or without csDMARDs; 2) csDMARD-exposed: any csDMARD without b/tsDMARD. Patients could contribute time to different exposure groups if they changed medications. Incident dementia was defined as: 1 inpatient OR 2 outpatients ICD-9-CM or ICD-10 claims for dementia, OR prescription of a dementia-specific medication (rivastigmine, galantamine, memantine, donepezil, tacrine). Age-adjusted incident rates (IR) were calculated, and univariate and multivariate Cox proportional hazard models were used to calculate Hazard Ratios (HR) and 95% confidence intervals (CI). RESULTS: We identified 141,326 eligible RA patients; 80% female and 75.3% white, median age 67 years and mean (SD) exposure time of 1.1 (1.5) years. There were 233,271 initiations of c/b/tsDMARDS and 3,794 cases of incident dementia during follow up. The crude IR of dementia was 2.0 (95% CI 1.9-2.1) per 100 person-years for patients on csDMARDs and 1.3 (95% CI 1.2-1.4) for patients on any b/tsDMARD. Patients on b/tsDMARDs had an adjusted 19% lower risk for dementia than patients on csDMARDs [HR 0.81 (95% CI 0.76-0.87)]. Subgroup analysis found comparable risk reductions between TNFi, non-TNFi, and tsDMARDs. on the risk of dementia. CONCLUSIONS AND RELEVANCE: The incidence of dementia in patients with RA was lower in patients receiving b/tsDMARDs when compared to patients on csDMARD only. No differences were observed between different classes of b/tsDMARDs, suggesting that decreased risk is possibly explained by the overall decrease in inflammation rather than a specific mechanism of action of these drugs.
引用
- Sattui SE, Navarro-Millan I, Xie F, et al. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database. Semin Arthritis Rheum. 2022. PMID: 36155968. doi:10.1016/j.semarthrit.2022.152083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。